Role of Enterprises in National & Global Economy MCQs With Answer

Introduction: Role of Enterprises in National & Global Economy MCQs With Answer is tailored for M.Pharm students to deepen understanding of how enterprises—especially pharmaceutical firms—shape economic growth, public health, and innovation ecosystems. This set of focused multiple-choice questions explores enterprise contributions to GDP, employment, exports, technology transfer, regulatory harmonization, supply-chain resilience, and public–private partnerships. Emphasis is placed on real-world implications for pharmaceutical industry structure, research and development, intellectual property, and global value chains. These MCQs will help postgraduate pharmacy students connect managerial and economic concepts with sector-specific challenges and opportunities, preparing them for roles in industry, policy analysis, and entrepreneurship.

Q1. What is the primary way enterprises contribute directly to national GDP?

• Providing public goods such as roads and schools
• Government tax collection
• Producing goods and services sold in markets
• Setting monetary policy

Correct Answer: Producing goods and services sold in markets

Q2. Which role of enterprises is most critical for fostering pharmaceutical innovation?

• Mass production of generic products only
• Investment in R&D and clinical trials
• Limiting exports to protect domestic supply
• Reducing workforce training to cut costs

Correct Answer: Investment in R&D and clinical trials

Q3. How do small and medium enterprises (SMEs) in pharma primarily support national economic resilience?

• By monopolizing raw material distribution
• By creating diversified supply chains and local employment
• By solely focusing on luxury health products
• By eliminating competition with multinational corporations

Correct Answer: By creating diversified supply chains and local employment

Q4. Which mechanism allows multinational pharmaceutical enterprises to influence global pricing and accessibility?

• Local advertising campaigns only
• Control over intellectual property and licensing agreements
• Setting national tax laws
• Restricting academic publications

Correct Answer: Control over intellectual property and licensing agreements

Q5. What is a key economic benefit of pharmaceutical clusters (industry hubs) in a region?

• Increased regulatory burden for all companies
• High coordination costs with no innovation benefit
• Knowledge spillovers, skilled workforce concentration, and supplier networks
• Guaranteed monopoly pricing for firms inside the cluster

Correct Answer: Knowledge spillovers, skilled workforce concentration, and supplier networks

Q6. How do enterprises contribute to employment quality in the pharmaceutical sector?

• By replacing skilled labor with unskilled automation only
• By providing jobs with training, career pathways, and professional development
• By outsourcing all research functions abroad
• By discouraging regulatory compliance to cut costs

Correct Answer: By providing jobs with training, career pathways, and professional development

Q7. Which enterprise practice most directly improves access to medicines in low-income countries?

• Prioritizing high-margin specialty drugs exclusively
• Tiered pricing, voluntary licensing, and local manufacturing partnerships
• Strict enforcement of patents without exceptions
• Export restrictions on active pharmaceutical ingredients (APIs)

Correct Answer: Tiered pricing, voluntary licensing, and local manufacturing partnerships

Q8. What is the significance of foreign direct investment (FDI) by pharmaceutical firms for the host economy?

• It reduces local R&D capacity permanently
• It brings capital, technology transfer, and integration into global value chains
• It always displaces domestic firms through hostile takeovers
• It eliminates need for local regulation

Correct Answer: It brings capital, technology transfer, and integration into global value chains

Q9. Which is a systemic risk when pharmaceutical enterprises pursue extreme global sourcing strategies?

• Stronger local manufacturing ecosystems
• Supply-chain fragility and dependencies on single-source suppliers
• Lower unit costs with no downside
• Permanent reduction in global trade

Correct Answer: Supply-chain fragility and dependencies on single-source suppliers

Q10. In the context of national policy, enterprises can accelerate health outcomes most effectively through:

• Ignoring public–private partnerships
• Collaborating with governments on vaccination programs and drug distribution
• Lobbying to restrict access to generics
• Focusing only on international markets and neglecting local needs

Correct Answer: Collaborating with governments on vaccination programs and drug distribution

Q11. How does corporate social responsibility (CSR) by pharmaceutical enterprises influence the broader economy?

• By decreasing community health and increasing costs
• By enhancing public trust, improving population health, and supporting workforce productivity
• By compressing R&D investment to fund charity
• By removing the need for regulatory oversight

Correct Answer: By enhancing public trust, improving population health, and supporting workforce productivity

Q12. What role do patents play in balancing enterprise incentives and public health?

• They permanently block any competition regardless of need
• They provide temporary exclusivity to incentivize R&D while eventual generic entry increases access
• They ensure immediate universal access to new drugs
• They are irrelevant to pharmaceutical markets

Correct Answer: They provide temporary exclusivity to incentivize R&D while eventual generic entry increases access

Q13. Which global mechanism helps harmonize pharmaceutical regulation across countries to facilitate trade?

• Local municipal bylaws
• International Council for Harmonisation (ICH) guidelines
• National tax codes only
• Randomized pricing agreements

Correct Answer: International Council for Harmonisation (ICH) guidelines

Q14. What is a major economic advantage of vertical integration for a pharmaceutical enterprise?

• Complete isolation from market signals
• Better control over quality, cost, and supply continuity across production stages
• Guaranteed elimination of all competitors
• Lower accountability to regulatory authorities

Correct Answer: Better control over quality, cost, and supply continuity across production stages

Q15. Which policy tool can governments use to encourage enterprise investment in neglected-disease R&D?

• Cutting research grants entirely
• Advanced market commitments, tax incentives, and public–private partnerships
• Prohibiting foreign collaboration
• Strict price controls preventing any return on investment

Correct Answer: Advanced market commitments, tax incentives, and public–private partnerships

Q16. How do enterprises add value in global value chains for pharmaceuticals?

• By concentrating exclusively on final retailing
• By specializing in stages like API production, formulation, clinical trials, or distribution to increase efficiency
• By avoiding any collaboration with suppliers
• By keeping all operations within one country regardless of cost

Correct Answer: By specializing in stages like API production, formulation, clinical trials, or distribution to increase efficiency

Q17. What is the likely economic effect when enterprises invest in digitalization and process automation in pharma?

• Permanent loss of product quality
• Improved manufacturing efficiency, faster scale-up, and potential job shifts requiring reskilling
• Complete elimination of regulatory requirements
• Reduction in global market opportunities

Correct Answer: Improved manufacturing efficiency, faster scale-up, and potential job shifts requiring reskilling

Q18. Which indicator best reflects an enterprise’s contribution to a country’s external sector?

• Number of local internships offered
• Export volumes and balance of trade contribution
• Length of CEO tenure
• Number of internal meetings held

Correct Answer: Export volumes and balance of trade contribution

Q19. During a pandemic, what enterprise behavior most strengthens national public health response?

• Prioritizing profits by withholding critical products from local markets
• Scaling production, sharing know-how, and coordinating with health authorities
• Refusing to collaborate on clinical data sharing
• Lobbying to delay emergency authorizations

Correct Answer: Scaling production, sharing know-how, and coordinating with health authorities

Q20. Which fiscal measure can a government use to support enterprise-led innovation in the pharmaceutical industry?

• Increasing tariffs on R&D equipment imports without exemptions
• Offering R&D tax credits, grants, and accelerated depreciation for lab investments
• Prohibiting foreign scientific collaboration
• Eliminating all intellectual property protections

Correct Answer: Offering R&D tax credits, grants, and accelerated depreciation for lab investments

Download